Home >

Welcome to ASCO Connection Discussion

The ASCO Connection Discussion forum is a space for oncology professionals and others with an interest in cancer care to ask and answer questions about every aspect of the field, from professional development advice to clinical conundrums. Everyone is welcome to participate: to ask a question or leave a response, first log in with your ASCO username and password. Please read the Discussion and Commenting Guidelines before you post a question or response. Contact our staff by email for assistance with the Discussion forum.

LOGIN TO START A DISCUSSION
Filter by All Topics
William Nassib William, Jr., MD
Feb 17, 2016 12:48 PM
Welcome to this discussion forum for the Metastatic Squamous Cell Lung Cancer Tumor Board. This course discussed a 63 year old woman with a history of hypertension who presented to her primary care physician with a two-month history of shortness of breath on moderate exertion and a dry cough. The...
Molecular Oncology Tumor Board
ASCO University
Feb 10, 2016 9:49 AM
Read more to answer the following questions: 1) Choice for site of biopsy? LN vs. Bone and merits/pros/cons for tissue for molecular profiling vs. confirmation of distant recurrence? 2) Would you recommend clinical genetics consultation for BRCA testing?  Expanded panel testing? 3) What additional...
William K. Oh, MD
Jan 20, 2016 9:07 AM
Welcome to this discussion forum for the Locally Advanced Prostate Cancer ASCO Tumor Board. This course discussed a 54 year old African American man with a history of atrial fibrillation and myocardial infarction, had a coronary artery bypass in 2015. Ejection fraction is now at 45%. He has...
Practice
Arsh Singh, MD
Jan 18, 2016 1:00 PM
In a 33 y/o caucasian woman with T2N0 Her 2 Positive invasive ductal carcinoma (both by IHC and FISH), ER 50% and PR negative, is it okay to use AC followed by T along with herceptin and pertuzumab  in the neoadjuvant setting?
Molecular Oncology Tumor Board
ASCO University
Jan 13, 2016 9:19 AM
Read more to answer the following questions: 1) What are the pathologic features that distinguish PEComa from the much more common leiomyosarcoma? 2) What is the role for cytotoxic chemotherapy in the treatment of metastatic or unresectable PEComa? 3) Are there any particular genetic targets...

Pages

Tweets from ASCO

Tweets from Oncology Community